Technical Momentum and Price Action
Concord Biotech’s current price of ₹1,520.85 marks a significant recovery from its 52-week low of ₹987.05, though it remains below the 52-week high of ₹1,800.00. The stock’s daily trading range today spanned ₹1,440.55 to ₹1,535.00, indicating strong intraday volatility and buying interest. This price action aligns with the technical trend upgrade from mildly bullish to bullish, suggesting that momentum is gaining traction.
On a relative basis, Concord Biotech has outperformed the Sensex considerably over recent periods. The stock posted a 7.33% return in the past week against the Sensex’s decline of 1.04%, and a 13.53% gain over the last month compared to the Sensex’s 0.54% fall. Year-to-date, Concord Biotech has delivered a 13.04% return while the benchmark index is down 8.79%. These figures underscore the stock’s resilience amid broader market weakness.
MACD and Moving Averages Signal Strengthening Uptrend
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On the weekly chart, the MACD is bullish, signalling upward momentum, while the monthly MACD remains mildly bearish, indicating some longer-term caution. This divergence suggests that while short-term momentum is improving, investors should monitor monthly trends for confirmation of sustained strength.
Daily moving averages reinforce the bullish case, with the stock trading above key averages, signalling positive short-term momentum. This is a critical technical confirmation, as moving averages often act as dynamic support and resistance levels. The bullish daily moving averages suggest that the recent price gains are supported by underlying strength rather than speculative spikes.
RSI and Bollinger Bands: Mixed Signals but Overall Positive
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, hovering in neutral zones. This indicates that the stock is neither overbought nor oversold, leaving room for further price appreciation without immediate risk of a technical pullback.
Bollinger Bands, however, provide a more optimistic outlook. Both weekly and monthly Bollinger Bands are bullish, implying that price volatility is expanding upwards and the stock is trending towards the upper band. This often precedes continued upward price movement, signalling that Concord Biotech could sustain its rally in the near term.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Other Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator presents a bearish signal on the weekly chart, suggesting some short-term caution. However, the monthly KST reading is not available, limiting longer-term interpretation. This bearish weekly KST contrasts with other bullish signals, indicating that investors should watch for potential short-term corrections.
Dow Theory assessments are mildly bullish on both weekly and monthly timeframes, reinforcing the notion of an emerging uptrend. This theory, which analyses market phases and trends, supports the technical upgrade and suggests that the stock may be entering a more sustained bullish phase.
On-Balance Volume (OBV) readings show no clear trend on the weekly chart and a mildly bearish stance on the monthly chart. This mixed volume analysis implies that while price momentum is improving, volume support is not yet fully convincing, warranting cautious optimism.
MarketsMOJO Rating Upgrade and Market Capitalisation
Reflecting these technical improvements, MarketsMOJO has upgraded Concord Biotech’s Mojo Grade from Sell to Hold as of 31 July 2026. The current Mojo Score stands at 57.0, indicating moderate confidence in the stock’s prospects. The company remains classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility but also growth potential.
Investors should note that despite the recent positive momentum, the stock’s one-year return remains negative at -7.12%, though this underperformance is less severe than the Sensex’s -3.56% over the same period. Longer-term returns over three, five, and ten years are not available, but the sector’s overall performance and the company’s recent technical upgrades suggest a potential turnaround.
Considering Concord Biotech Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Investor Takeaway and Outlook
Concord Biotech’s recent technical parameter changes signal a positive shift in momentum, supported by bullish MACD on weekly charts, daily moving averages, and Bollinger Bands. The upgrade in MarketsMOJO rating from Sell to Hold further validates this improving outlook. However, mixed signals from the monthly MACD, KST, and OBV indicators counsel prudence, suggesting that investors should monitor volume trends and longer-term momentum before committing heavily.
Given the stock’s strong relative performance against the Sensex in recent weeks and months, it appears well-positioned to capitalise on sectoral tailwinds in Pharmaceuticals & Biotechnology. Yet, the absence of a clear RSI signal and some bearish volume indicators imply that short-term volatility may persist.
For investors with a medium-term horizon, Concord Biotech offers an intriguing proposition as a small-cap stock exhibiting early signs of technical recovery. Those seeking more conservative or diversified exposure may consider comparing alternatives within the sector, as highlighted by recent thematic analyses.
Summary of Key Technical Metrics:
- Current Price: ₹1,520.85 (up 5.17% today)
- 52-Week Range: ₹987.05 – ₹1,800.00
- MACD: Weekly Bullish, Monthly Mildly Bearish
- RSI: Neutral on Weekly and Monthly
- Bollinger Bands: Bullish on Weekly and Monthly
- Moving Averages: Daily Bullish
- KST: Weekly Bearish
- Dow Theory: Mildly Bullish Weekly and Monthly
- OBV: No Trend Weekly, Mildly Bearish Monthly
- MarketsMOJO Mojo Score: 57.0 (Hold, upgraded from Sell)
Investors should continue to track these indicators closely as Concord Biotech navigates the evolving market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
